Jade Biosciences (NASDAQ:JBIO) Earns Buy Rating from HC Wainwright

Key Points

• HC Wainwright reaffirmed a “buy” rating on Jade Biosciences and set a $55 price target, implying roughly 291% upside from the referenced $14.05 share price. The broader analyst consensus is “Moderate Buy,” with an average target of $51.75.
• Jade’s investigational JADE301 antibody showed encouraging preclinical results, including selective IFN-β binding, greater potency than a comparator, an approximately 25-day half-life in non-human primates, and good tolerability.
• The company expects to begin a Phase 1 healthy-volunteer trial in the fourth quarter of 2026, but the candidate remains unproven clinically. Jade also missed its latest quarterly EPS estimate, reporting a loss of $0.76 per share versus the expected $0.66 loss.

Jade Biosciences (NASDAQ:JBIO - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a research report issued on Thursday, Marketbeat Ratings reports. They presently have a $55.00 price objective on the stock. HC Wainwright's target price would indicate a potential upside of 291.46% from the company's previous close.

Several other brokerages have also recently commented on JBIO. Wall Street Zen cut shares of Jade Biosciences from a "sell" rating to a "strong sell" rating in a research report on Saturday, September 12th. BTIG Research increased their price target on shares of Jade Biosciences from $74.00 to $77.00 and gave the stock a "buy" rating in a research report on Monday, August 10th. UBS Group began coverage on shares of Jade Biosciences in a research report on Monday, June 15th. They set a "buy" rating and a $45.00 price objective for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Jade Biosciences in a report on Friday, September 11th. Finally, Wedbush reiterated an "outperform" rating and issued a $47.00 price target on shares of Jade Biosciences in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $51.75.

Jade Biosciences Stock Performance

Shares of Jade Biosciences stock opened at $14.05 on Thursday. The firm has a market cap of $893.58 million, a PE ratio of -7.32 and a beta of 1.45. Jade Biosciences has a 52-week low of $8.16 and a 52-week high of $28.00. The business's 50 day simple moving average is $19.69 and its 200 day simple moving average is $19.74.

Jade Biosciences (NASDAQ:JBIO - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, equities research analysts predict that Jade Biosciences will post -2.89 EPS for the current year.

Institutional Investors Weigh In On Jade Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quantinno Capital Management LP increased its position in Jade Biosciences by 3.6% during the first quarter. Quantinno Capital Management LP now owns 30,551 shares of the company's stock worth $429,000 after buying an additional 1,059 shares in the last quarter. Bank of America Corp DE raised its holdings in Jade Biosciences by 2.9% in the 1st quarter. Bank of America Corp DE now owns 38,598 shares of the company's stock valued at $542,000 after acquiring an additional 1,086 shares during the last quarter. Squarepoint Ops LLC boosted its holdings in shares of Jade Biosciences by 22.0% during the second quarter. Squarepoint Ops LLC now owns 54,456 shares of the company's stock worth $1,210,000 after purchasing an additional 9,806 shares during the last quarter. Engineers Gate Manager LP acquired a new position in Jade Biosciences in the second quarter valued at $503,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Jade Biosciences in the 1st quarter worth about $353,000.

Key Stories Impacting Jade Biosciences

Here are the key news stories impacting Jade Biosciences this week:

• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and assigned a $55 price target, implying approximately 291.5% upside from the referenced $14.05 share price. The target signals substantial analyst confidence in Jade’s pipeline and could improve investor sentiment. Benzinga analyst rating report
• Positive Sentiment: Jade reported preclinical data for JADE301, a half-life-extended anti-IFN-β monoclonal antibody being developed for dermatomyositis. The candidate showed selective, high-affinity IFN-β binding and greater functional potency than the dazukibart comparator in disease-relevant human cells. Jade Biosciences JADE301 preclinical data announcement
• Positive Sentiment: In non-human primates, subcutaneous JADE301 demonstrated an approximately 25-day half-life, predictable distribution into muscle and good tolerability across tested doses. These characteristics could support less frequent dosing and a differentiated product profile if confirmed clinically. Jade Biosciences advances JADE301 toward Phase 1
• Neutral Sentiment: Jade expects to begin a Phase 1 healthy-volunteer trial in the fourth quarter of 2026, with interim data anticipated in the second half of 2027. The clinical timeline provides a near-term catalyst, but meaningful efficacy and safety validation remain ahead. Jade Biosciences JADE301 announcement
• Negative Sentiment: The data are preclinical and do not establish that JADE301 will benefit patients or succeed in clinical trials. With shares below their 50-day and 200-day moving averages, investors may remain sensitive to development delays, trial setbacks and future financing needs.

About Jade Biosciences

Jade Biosciences, Inc NASDAQ: JBIO is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory diseases. The company uses antibody-based drug discovery and development approaches to pursue therapies intended to address significant unmet medical needs.

Jade Biosciences is advancing a pipeline of investigational programs and does not currently have commercially marketed products. Its work is centered on identifying and developing targeted therapies that may modulate biological pathways involved in autoimmune disease.

The company's activities primarily consist of research, preclinical development and clinical evaluation of its drug candidates.